The African Malaria Network Trust (AMANET) is a pan-African non-governmental organization that sponsors and technically supports malaria vaccine trials in various African countries.
Case see more description: AMANET sponsored phase Ib or IIb clinical trials of several malaria vaccine candidates in various Africa countries. In Burkina Faso, Mali and Tanzania trials of
the merozoite surface protein 3 – in its Long Synthetic Peptide configuration (MSP3 LSP) – were conducted. In Mali, the apical membrane antigen 1 (AMA1)was tested, while a hybrid of glutamate rich protein (GLURP) and MSP3 (GMZ2) was tested in Gabon. AMANET recognizes the importance of engaging with the communities from which trial participants are drawn, hence community engagement was given priority Panobinostat datasheet in all project activities conducted in the various countries.
Discussion and evaluation: Existing local social systems were used to engage the communities from which clinical trial participants were drawn. This article focuses on community engagement activities employed at various AMANET-supported clinical trial sites in different countries, highlighting subtle differences in the approaches used. The paper also gives some general pros and cons
of community engagement.
Conclusions: Community engagement enables two-way sharing of accurate information and ideas between researchers and researched communities, which helps to create an environment conducive to smooth research activities HSP990 mouse with enhanced sense of research ownership by the communities.”
“Background: Severe anemia (hemoglobin <70 g/L) in pregnancy may increase the risk of maternal and perinatal mortality.
Objectives: We assessed response to standard treatment with high-dose iron-folic
acid for 90 d and single-dose (500 mg) mebendazole among severely anemic pregnant women in periurban Karachi, Pakistan. In addition, we evaluated the efficacy of 2 enhanced treatment regimens.
Design: We screened pregnant women (n=6288) for severe anemia and provided them all with the standard treatment. To test the efficacy of 2 additional treatments, women were randomly assigned to standard treatment alone (control) or with 100 mg mebendazole twice daily for 3 d or 90 d of daily multivitamins or both using a 2 x 2 factorial design.
Results: Prevalence of severe anemia was high (10.5%) during pregnancy. Prevalence of geohelminths and malaria was low. Treatment response was defined as hemoglobin >100 g/L at the 90-d or >= 25 g/L at the 60-d follow-up visit. The standard-of-care treatment resulted in a response rate of 49% at follow-up, although an adherence of >= 85% elicited a higher response (67%). The effect of the additional treatments was weak.